LCAHA (LCA hydroxyamide) is a deubiquitinase USP2a inhibitor with IC 50 s of 9.7 μM and 3.7μM in Ub-AMC Assay and Di-Ub Assay, respectively. LCAHA destabilizes Cyclin D1 and induces G0/G1 arrest by inhibiting deubiquitinase USP2a.In VitroLCAHA inhibits HCT116 wt and HCT116 p53 -/- colon cancer cells viability with GI 50 s of 0.87±0.09 and 0.96±0.29μM, respectively, and the LD 50 s of 27.8±3.9 and 26.5±0.1μM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HCT116 wt and HCT116 p53 -/- colon cancer cells Concentration: 0.01, 0.1, 1, 10, and 100 μM Incubation Time: 6 days Result: The GI 50 s are 0.87±0.09 and 0.96±0.29 μM for HCT116 wt and HCT116 p53 -/- colon cancer cells, respectively.Form:Solid. Specifications and Purity: 98%. Molecular Formula: C24H41NO3. Molecular Weight: 391.59.
- UPC:
- 12352005
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.06 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- L649981-100mg
- CAS:
- 117094-40-3
- Product Size:
- 100mg
